Pharma & Biotech
Advanced Oncotherapy uses proton beam therapy to target resistant cancers
Nuformix eyes big opportunity with new forms of fibrosis and cancer drugs
Nuformix looks to broaden reach of key drug developments
Only registered members can use this feature.
© Proactive 2021.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.